Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%

Rhea-AI Summary

Abiomed's recent study highlights a significant advancement in treating AMI cardiogenic shock patients using Impella devices. Conducted across 109 hospitals in Japan, the study found a 30-day survival rate of 81% among 1,344 patients, a stark improvement from the historical rate of approximately 50%. Presented at the 2022 TCT conference, these results reinforce the efficacy of Impella in enabling heart recovery when combined with best practices. The findings align with similar studies, suggesting a consistent trend in improved survival rates with Impella usage.

Positive

• 30-day survival rate for AMI cardiogenic shock patients using Impella is 81%, significantly higher than the historical rate of 50%.
• Study strengthens the credibility of Impella devices in clinical practice, supporting enhanced patient outcomes.

Negative

• None.

BOSTON--(BUSINESS WIRE)-- Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston.

Caption: The investigator-led Inova, NCSI and J-PVAD studies all demonstrate an improvement from the historical AMI cardiogenic shock survival rate of approximately 50% when patients are treated with best practices including Impella. (Graphic: Business Wire)

The analysis examined 293 consecutive Impella-supported AMICS patients in the J-PVAD Registry, a registry conducted by 10 Japanese professional societies, including the Japanese Circulation Society (JCS). Results demonstrated 81% survival at 30 days. Historical cardiogenic shock survival rates without Impella are approximately 50%.

“The results of this study demonstrate that when Impella is used and best practices are followed, it is possible to achieve heart recovery and greater than 80% survival rates for patients with AMI cardiogenic shock,” said lead investigator Junya Ako, MD, an interventional cardiologist and chair of the department of cardiovascular medicine at Kitasato University Hospital in Kanagawa.

These results are consistent with other published investigator-led studies, such as the National Cardiogenic Shock Initiative Study (NCSI) and the Inova study by Tehrani et al., that have demonstrated significant increases in survival with the use of Impella and best practices such as placing Impella prior to percutaneous coronary intervention (PCI) (see figure 1).

J-PVAD data is independently monitored and shared with the Japan Pharmaceuticals and Medical Devices Agency (PMDA).

ABOUT IMPELLA HEART PUMPS

Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.

ABOUT ABIOMED

Based in Danvers, Massachusetts, USA, Abiomed (ABMD), is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005279/en/

For further information:

Media:

Jenny Leary

Associate Director, U.S. Communications

+1 (978) 882-8491

jleary@abiomed.com

Investor:

Todd Trapp

Executive Vice President and Chief Financial Officer

+1 (978) 646-1680

ttrapp@abiomed.com

Source: Abiomed, Inc.

FAQ

What are the results of the recent study on Impella devices by Abiomed?

The study showed a 30-day survival rate of 81% for AMI cardiogenic shock patients treated with Impella, significantly improving upon the historical rate.

How many patients were involved in the Impella study conducted in Japan?

The study involved 1,344 patients treated at 109 hospitals in Japan.

At which conference was the Impella study presented?

The findings were presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.

What does the Impella study suggest about patient outcomes?

The study suggests that using Impella in conjunction with best practices can lead to improved patient recovery and survival rates.

What does the historical survival rate for AMI cardiogenic shock patients indicate?

Historically, the survival rate for AMI cardiogenic shock patients without Impella treatment is about 50%.